Sandoz Says Xarelto Dosing Info Was Public Before Patenting
Counsel for Sandoz told a London court Monday that patent protections underpinning Xarelto, Bayer's best-selling drug, are obvious, claiming that the German pharmaceutical giant published data on the dosing regimen for...To view the full article, register now.
Already a subscriber? Click here to view full article